Home » Obesity » 2007 for a scheduled pre-Investigational New Medication conference on Revimmune.

Accentia announces investigational new medication program for Revimmune for refractory MS Accentia Biopharmaceuticals has announced that it met with the Food and Drug Administration on September 26, 2007 for a scheduled pre-Investigational New Medication conference on Revimmune. The FDA has indicated its support for Accentia to submit an IND for a pivotal Phase 3 randomized controlled, multi-center scientific trial of Revimmune, the company’s potential therapeutic for refractory, relapsing-remitting Multiple Sclerosis http://www.clomidhelp.com . The FDA indicated that they support the proposed submission from Accentia and they are in overall contract with the proposed design of the Accentia medical plan. The Revimmune MS research will enroll subjects in a one-year study evaluating baseline disability to disability at month 12 with an interim data analysis.